The success and the challenge of all-trans retinoic acid in the treatment of cancer

Abstract

All-trans retinoic acid (ATRA), an active metabolite of vitamin A, plays important roles in cell proliferation, cell differentiation, apoptosis, and embryonic development. The effects of ATRA are mediated by nuclear retinoid receptors as well as non-genomic signal pathway, such as MAPK and PKA. The great success of differentiation therapy with ATRA in acute promyelocytic leukemia (APL) not only improved the prognosis of APL but also spurred the studies of ATRA in the treatment of other tumors. Since the genetic and physiopathological simplicity of APL is not common in human malignancies, the combination of ATRA with other agents (chemotherapy, epigenetic modifiers, and arsenic trioxide, etc) had been extensively investigated in a variety of tumors. In this review, we will discuss in details about ATRA and its role in cancer treatment.

Keywords:

• All-trans retinoic acid
• acute promyelocytic leukemia
• retinoic acid receptors
• chemotherapy
• epigenetic modifiers
• differentiation

Additional information

Funding

This work is supported by the Natural Science Foundation of Shanghai (17ZR1417100).